Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,373 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,067 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (618)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03434379 | A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma(IMbrave150) | completed | Phase 3 | 558 | Hoffmann-La RocheINDUSTRY | 17 | Oct 23, 2023 | clinicaltrials |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy(POLO) | completed | Phase 3 | 154 | AstraZenecaINDUSTRY |
| 12 |
| Sep 13, 2023 |
| clinicaltrials |
| NCT00699816 | Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients | completed | Phase 3 | 230 | GC Cell CorporationINDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT02973685 | HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B. | completed | Phase 3 | 315 | Sun Yat-sen UniversityOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT03126435 | EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX | completed | Phase 3 | 218 | SynCore Biotechnology Co., Ltd.INDUSTRY | 7 | May 6, 2023 | clinicaltrials |
| NCT02494583 | Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) | completed | Phase 3 | 763 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 13, 2023 | clinicaltrials |
| NCT02438436 | Simo Decoction and Gum Chewing for Bowel Activity(SD/GC-HCC) | completed | Phase 3 | 180 | Guangxi Medical UniversityOTHER | 1 | Jan 30, 2023 | clinicaltrials |
| NCT02435433 | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein(REACH-2) | completed | Phase 3 | 399 | Eli Lilly and CompanyINDUSTRY | 20 | Jan 20, 2023 | clinicaltrials |
| NCT03665441 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC(Trybeca-1) | completed | Phase 3 | 512 | ERYtech PharmaINDUSTRY | 3 | Oct 18, 2022 | clinicaltrials |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | completed | Phase 3 | 413 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 29, 2022 | clinicaltrials |
| NCT03042611 | A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer(ANGEL) | completed | Phase 3 | 460 | Elevar TherapeuticsINDUSTRY | 12 | Jul 8, 2022 | clinicaltrials |
| NCT02898077 | A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer | completed | Phase 3 | 440 | Eli Lilly and CompanyINDUSTRY | 4 | Jun 14, 2022 | clinicaltrials |
| NCT02370498 | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | completed | Phase 3 | 592 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 6, 2022 | clinicaltrials |
| NCT01962246 | Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction(A-C) | completed | Phase 2 / Phase 3 | 169 | Hebei Medical UniversityOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT02314117 | A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer(RAINFALL) | completed | Phase 3 | 645 | Eli Lilly and CompanyINDUSTRY | 20 | Aug 26, 2021 | clinicaltrials |
| NCT00487695 | Confocal Endomicroscopy for Barrett's Esophagus(CEBE) | completed | Phase 3 | 46 | Johns Hopkins UniversityOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT01655693 | Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma(ReLive) | completed | Phase 3 | 397 | Valerio TherapeuticsINDUSTRY | 11 | Jun 2, 2021 | clinicaltrials |
| NCT01455831 | Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer(PERIOP-01) | completed | Phase 3 | 616 | Ottawa Hospital Research InstituteOTHER | 3 | May 17, 2021 | clinicaltrials |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib(CELESTIAL) | completed | Phase 3 | 707 | ExelixisINDUSTRY | 19 | May 6, 2021 | clinicaltrials |
| NCT01755767 | Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy(METIV-HCC) | completed | Phase 3 | 383 | Daiichi SankyoINDUSTRY | 16 | Apr 6, 2021 | clinicaltrials |
| NCT01107639 | Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery | completed | Phase 3 | 297 | Swiss Cancer InstituteOTHER | 5 | Oct 20, 2020 | clinicaltrials |
| NCT01774344 | Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma(RESORCE) | completed | Phase 3 | 573 | BayerINDUSTRY | 21 | Aug 20, 2020 | clinicaltrials |
| NCT02545504 | Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma(GAMMA-1) | completed | Phase 3 | 432 | Gilead SciencesINDUSTRY | 16 | May 26, 2020 | clinicaltrials |
| NCT01833299 | Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma | completed | Phase 3 | 120 | Sun Yat-sen UniversityOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT02774187 | Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC | completed | Phase 3 | 247 | Sun Yat-sen UniversityOTHER | 1 | Dec 5, 2019 | clinicaltrials |
| NCT00908752 | Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC(BRISK TA) | completed | Phase 3 | 734 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 2, 2019 | clinicaltrials |
| NCT01287585 | Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy(ADI-PEG 20) | completed | Phase 3 | 636 | Polaris GroupINDUSTRY | 6 | Sep 6, 2019 | clinicaltrials |
| NCT00096278 | Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer | completed | Phase 3 | 2,710 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 | clinicaltrials |
| NCT00901901 | Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma(SEARCH) | completed | Phase 3 | 732 | BayerINDUSTRY | 26 | May 30, 2019 | clinicaltrials |
| NCT01229839 | Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC | completed | Phase 3 | 668 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT01259414 | Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma | completed | Phase 3 | 812 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT00068692 | Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer | completed | Phase 3 | 225 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2018 | clinicaltrials |
| NCT03636620 | TACE Combined With RFA/MV Treatment in Hepatocellular Carcinoma Beyond Milan Criterial(TACE+RFA) | completed | Phase 3 | 110 | Fudan UniversityOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT00692770 | Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)(STORM) | completed | Phase 3 | 1,114 | BayerINDUSTRY | 28 | Aug 8, 2018 | clinicaltrials |
| NCT01829035 | A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC | completed | Phase 3 | 339 | National Cancer Center, KoreaOTHER_GOV | 1 | Mar 29, 2018 | clinicaltrials |
| NCT01265810 | Caphosol in Oral Mucositis Due to Targeted Therapy(COMTT) | completed | Phase 3 | 64 | Impaqtt FoundationOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT01901692 | Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion(START) | completed | Phase 2 / Phase 3 | 90 | Asan Medical CenterOTHER | 1 | Sep 18, 2017 | clinicaltrials |
| NCT00759109 | Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085) | completed | Phase 3 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 7, 2017 | clinicaltrials |
| NCT01804829 | Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients. | completed | Phase 3 | 80 | Biotest Pharmaceuticals CorporationINDUSTRY | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01360853 | Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer(ONTRAC) | completed | Phase 3 | 160 | Traws Pharma, Inc.INDUSTRY | 5 | Aug 4, 2016 | clinicaltrials |
| NCT02788526 | Adjuvant TACE to Reduce the HCC Recurrence After Resection | completed | Phase 3 | 180 | Sun Yat-sen UniversityOTHER | 1 | Jun 20, 2016 | clinicaltrials |
| NCT01964001 | The Effects of Vitamin B-6 and Coenzyme Q10 Status on Oxidative Stress, Antioxidant Capacities, and Inflammatory Responses in Patients With Liver Cancer | completed | Phase 2 / Phase 3 | 71 | Taichung Veterans General HospitalOTHER | 1 | Jun 15, 2016 | clinicaltrials |
| NCT00769106 | Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients After Resection of Liver Cancer(HCC-CIK) | completed | Phase 3 | 200 | Sun Yat-sen UniversityOTHER | 1 | Apr 14, 2016 | clinicaltrials |
| NCT01749865 | CIK Treatment for HCC Patient Underwent Radical Resection | completed | Phase 3 | 200 | Sun Yat-sen UniversityOTHER | 1 | Apr 14, 2016 | clinicaltrials |
| NCT00241020 | Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 3 | 270 | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 12, 2016 | clinicaltrials |
| NCT00814242 | Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels | completed | Phase 2 / Phase 3 | 120 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00820339 | Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy(SHVE) | completed | Phase 2 / Phase 3 | 132 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00827554 | The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma | completed | Phase 2 / Phase 3 | 100 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT01140347 | A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib(REACH) | completed | Phase 3 | 565 | Eli Lilly and CompanyINDUSTRY | 27 | Dec 28, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Oct 23, 2023source: clinicaltrials